« Back
Home /
Lucerastat

Lucerastat

Item no.	TMO-T32923-500mg
Manufacturer	TargetMol
CASRN	141206-42-0
Amount	500 mg
Quantity options	100 mg 25 mg 500 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Formula	C10H21NO4
Smiles	C(CCC)N1[C@H](CO)[C@H](O)[C@H](O)[C@@H](O)C1
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	NB DGJ,N-(n-Butyl)deoxygalactonojirimycin,ACT 434964,NBDGJ,OGT 923
Shipping Condition	Cool pack
Available
Manufacturer - Targets	Transferase
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	219.28
Description	Lucerastat（NBDGJ） is an orally available inhibitor of Glucosylceramide Synthase (GCS) with therapeutic potential for Fabry disease. GCS is a key enzyme in sphingolipid synthesis and inhibition of its activity reduces the accumulation of harmful substrates.
Pathways	Metabolism
Bioactivity	Lucerastat is a very effective and selective Î±-gal A (Î±-D-galactosidase) inhibitor for the treatment of lipid storage diseases and Fabry disease.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T32923-500mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 500 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question